{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:21:14Z","timestamp":1778750474783,"version":"3.51.4"},"reference-count":53,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2021,7,14]],"date-time":"2021-07-14T00:00:00Z","timestamp":1626220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The in vivo correct QT (QTc) assay is used by the pharmaceutical industry to characterize the potential for delayed ventricular repolarization and is a core safety assay mentioned in International Conference on Harmonization (ICH) S7B guideline. The typical telemetry study involves a dose\u2010response analysis of QTc intervals over time using a crossover (CO) design. This method has proven utility but does not include direct integration of pharmacokinetic (PK) data. An alternative approach has been validated and is used routinely in the clinical setting that pairs pharmacodynamic (PD) responses with PK exposure (e.g., concentration\u2010QTc (C\u2010QTc) analysis. The goal of our paper was to compare the QTc sensitivity of two experimental approaches in the conscious dog and non\u2010human primate (NHP) QTc assays. For timepoint analysis, a conventional design using eight animals (8\u00a0\u00d7\u00a04\u00a0CO) to detect moxifloxacin\u2010induced QTc prolongation was compared to a PK\/PD design in a subset (<jats:italic>N<\/jats:italic>\u00a0=\u00a04) of the same animals. The findings demonstrate that both approaches are equally sensitive in detecting threshold QTc prolongation on the order of 10\u00a0ms. Both QTc models demonstrated linearity in the QTc prolongation response to moxifloxacin dose escalation (6 to 46\u00a0ms). Further, comparison with human QTc findings with moxifloxacin showed agreement and consistent translation across the three species: C\u2010QTc slope values were 0.7\u2010 (dog) and 1.2\u2010 (NHP) fold of the composite human value. In conclusion, our data show that dog and NHP QTc telemetry with an integrated PK arm (C\u2010QTc) has the potential to supplement clinical evaluation and improve integrated QTc risk assessment.<\/jats:p>","DOI":"10.1111\/cts.13103","type":"journal-article","created":{"date-parts":[[2021,6,26]],"date-time":"2021-06-26T04:14:02Z","timestamp":1624680842000},"page":"2379-2390","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Evaluation of moxifloxacin in canine and non\u2010human primate telemetry assays: Comparison of QTc interval prolongation by timepoint and concentration\u2010QTc analysis"],"prefix":"10.1111","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1162-8680","authenticated-orcid":false,"given":"Ray W.","family":"Chui","sequence":"first","affiliation":[{"name":"Amgen Research Thousand Oaks California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Baublits","sequence":"additional","affiliation":[{"name":"Amgen Research Thousand Oaks California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona A.","family":"Chandra","sequence":"additional","affiliation":[{"name":"Amgen Translational Medicine Thousand Oaks California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zack W.","family":"Jones","sequence":"additional","affiliation":[{"name":"Amgen Translational Medicine Thousand Oaks California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Engwall","sequence":"additional","affiliation":[{"name":"Amgen Research Thousand Oaks California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hugo M.","family":"Vargas","sequence":"additional","affiliation":[{"name":"Amgen Research Thousand Oaks California USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,7,14]]},"reference":[{"key":"e_1_2_9_2_1","unstructured":"Anonymous. ICH S7B: The non\u2010clinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals;2005."},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2011.03.002"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2014.05.004"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfu198"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2013.05.004"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14101"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2019.106606"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2029"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.QT-A4"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2006.05.001"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2008.12.004"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2004.02.006"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/pst.454"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2006.03.004"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2007.04.007"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2013.745851"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13218"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2013.04.006"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2010.05.011"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2009.05.006"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2021.107067"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.60"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9558-5"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12582"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13558"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-015-1760-9"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13123"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2013.03.007"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2015.04.007"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2011.08.006"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2009.04.196"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.12484"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2019.05.018"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2015.02.002"},{"key":"e_1_2_9_36_1","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.587149","article-title":"The effects of repeat\u2010dose doxorubicin on cardiovascular functional endpoints and biomarkers in the telemetry\u2010equipped cynomolgus monkey","volume":"8","author":"Engwall MJ","year":"2021","journal-title":"Front Cardiovascular Med"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2015.05.008"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.suppl_2.69"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1981.tb01123.x"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-020-09725-w"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010381498"},{"key":"e_1_2_9_42_1","unstructured":"Anonymous.ICH E14 Guideline: The Clinical Evaluation of QT\/QTc Interval Prolongation and Proarrhythmic Potential for Non\u2010Antiarrhythmic Drugs Questions & Answers (R3);2015."},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139873"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1283"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2000.111482"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2018.1520837"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.2005.00654.x"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2014.12.008"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706389"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2007.04.002"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vascn.2006.09.002"},{"key":"e_1_2_9_52_1","first-page":"72","article-title":"Effects of group housing on ECG assessment in conscious cynomolgus monkeys","volume":"73","author":"Xing G","year":"2015","journal-title":"J Pharmacol Toxicol Methods"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2137"},{"key":"e_1_2_9_54_1","doi-asserted-by":"crossref","first-page":"665","DOI":"10.4155\/bio-2020-0048","article-title":"Fluispotter, a novel automated and wearable device for accurate volume serial dried blood spot sampling","volume":"12","author":"Adhikari KB","year":"2020","journal-title":"Bioanalysis"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13103","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.13103","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.13103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T18:20:11Z","timestamp":1725301211000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.13103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,14]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1111\/cts.13103"],"URL":"https:\/\/doi.org\/10.1111\/cts.13103","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,14]]},"assertion":[{"value":"2021-03-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-14","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}